From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?

Filippo Alongi, Stefano Arcangeli, Sara Ramella, Niccolò Giaj-Levra, Paolo Borghetti, Rolando D’angelillo, Francesco Ricchetti, Marta Maddalo, Rosario Mazzola, Marco Trovò, Elvio Russi, Stefano Maria Magrini, the behalf of Associazione Italiana Radioterapia Oncologica (AIRO) on the behalf of Associazione Italiana Radioterapia Oncologica (AIRO)

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: The integration between radiotherapy and drugs, from chemotherapy to recently available target therapies, continues to have a relevant role in the treatment of locally advanced and metastatic Non-small cell lung cancer (NSCLC). Aim of the present review is to evaluate the promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy. Areas covered: We searched Medline, Google Scholar, PubMed, ProQuest Dissertation, and Theses databases for reports published in English. A study was included when it reported on cancer-related radiotherapy and included patients with NSCLC treated with chemo and/or target therapies. Review articles were excluded from the analysis. Expert commentary: Chemo-radiotherapy still represents the standard of choice in locally advanced NSCLC, while to date the addition of target therapies to chemo-radiotherapy did not demonstrate any robust advantage in this stage of disease. Considering the absence of randomized controlled trials, the role of target therapies in early stage adjuvant NSCLC is not yet recommended in clinical practice. On the contrary, in the setting of oligometastatic and oligoprogressive disease, new molecules demonstrated to be safe and effective, opening to a promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy.

Original languageEnglish
Pages (from-to)157-165
Number of pages9
JournalExpert Review of Anticancer Therapy
Volume17
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Marriage
Non-Small Cell Lung Carcinoma
Radiotherapy
Radiation
Drug Therapy
Therapeutics
Pharmaceutical Preparations
PubMed
Randomized Controlled Trials
Databases
Neoplasms

Keywords

  • early stage
  • locally advanced
  • Lung cancer
  • oligometastatic
  • radiotherapy
  • target therapies

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Alongi, F., Arcangeli, S., Ramella, S., Giaj-Levra, N., Borghetti, P., D’angelillo, R., ... on the behalf of Associazione Italiana Radioterapia Oncologica (AIRO), T. B. O. A. I. R. O. AIRO. (2017). From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage? Expert Review of Anticancer Therapy, 17(2), 157-165. https://doi.org/10.1080/14737140.2017.1273111

From chemotherapy to target therapies associated with radiation in the treatment of NSCLC : a durable marriage? / Alongi, Filippo; Arcangeli, Stefano; Ramella, Sara; Giaj-Levra, Niccolò; Borghetti, Paolo; D’angelillo, Rolando; Ricchetti, Francesco; Maddalo, Marta; Mazzola, Rosario; Trovò, Marco; Russi, Elvio; Magrini, Stefano Maria; on the behalf of Associazione Italiana Radioterapia Oncologica (AIRO), the behalf of Associazione Italiana Radioterapia Oncologica (AIRO).

In: Expert Review of Anticancer Therapy, Vol. 17, No. 2, 01.02.2017, p. 157-165.

Research output: Contribution to journalReview article

Alongi, F, Arcangeli, S, Ramella, S, Giaj-Levra, N, Borghetti, P, D’angelillo, R, Ricchetti, F, Maddalo, M, Mazzola, R, Trovò, M, Russi, E, Magrini, SM & on the behalf of Associazione Italiana Radioterapia Oncologica (AIRO), TBOAIROAIRO 2017, 'From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?', Expert Review of Anticancer Therapy, vol. 17, no. 2, pp. 157-165. https://doi.org/10.1080/14737140.2017.1273111
Alongi, Filippo ; Arcangeli, Stefano ; Ramella, Sara ; Giaj-Levra, Niccolò ; Borghetti, Paolo ; D’angelillo, Rolando ; Ricchetti, Francesco ; Maddalo, Marta ; Mazzola, Rosario ; Trovò, Marco ; Russi, Elvio ; Magrini, Stefano Maria ; on the behalf of Associazione Italiana Radioterapia Oncologica (AIRO), the behalf of Associazione Italiana Radioterapia Oncologica (AIRO). / From chemotherapy to target therapies associated with radiation in the treatment of NSCLC : a durable marriage?. In: Expert Review of Anticancer Therapy. 2017 ; Vol. 17, No. 2. pp. 157-165.
@article{2586946cdc504ba9af61a081ad4335ff,
title = "From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?",
abstract = "Introduction: The integration between radiotherapy and drugs, from chemotherapy to recently available target therapies, continues to have a relevant role in the treatment of locally advanced and metastatic Non-small cell lung cancer (NSCLC). Aim of the present review is to evaluate the promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy. Areas covered: We searched Medline, Google Scholar, PubMed, ProQuest Dissertation, and Theses databases for reports published in English. A study was included when it reported on cancer-related radiotherapy and included patients with NSCLC treated with chemo and/or target therapies. Review articles were excluded from the analysis. Expert commentary: Chemo-radiotherapy still represents the standard of choice in locally advanced NSCLC, while to date the addition of target therapies to chemo-radiotherapy did not demonstrate any robust advantage in this stage of disease. Considering the absence of randomized controlled trials, the role of target therapies in early stage adjuvant NSCLC is not yet recommended in clinical practice. On the contrary, in the setting of oligometastatic and oligoprogressive disease, new molecules demonstrated to be safe and effective, opening to a promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy.",
keywords = "early stage, locally advanced, Lung cancer, oligometastatic, radiotherapy, target therapies",
author = "Filippo Alongi and Stefano Arcangeli and Sara Ramella and Niccol{\`o} Giaj-Levra and Paolo Borghetti and Rolando D’angelillo and Francesco Ricchetti and Marta Maddalo and Rosario Mazzola and Marco Trov{\`o} and Elvio Russi and Magrini, {Stefano Maria} and {on the behalf of Associazione Italiana Radioterapia Oncologica (AIRO)}, {the behalf of Associazione Italiana Radioterapia Oncologica (AIRO)}",
year = "2017",
month = "2",
day = "1",
doi = "10.1080/14737140.2017.1273111",
language = "English",
volume = "17",
pages = "157--165",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - From chemotherapy to target therapies associated with radiation in the treatment of NSCLC

T2 - a durable marriage?

AU - Alongi, Filippo

AU - Arcangeli, Stefano

AU - Ramella, Sara

AU - Giaj-Levra, Niccolò

AU - Borghetti, Paolo

AU - D’angelillo, Rolando

AU - Ricchetti, Francesco

AU - Maddalo, Marta

AU - Mazzola, Rosario

AU - Trovò, Marco

AU - Russi, Elvio

AU - Magrini, Stefano Maria

AU - on the behalf of Associazione Italiana Radioterapia Oncologica (AIRO), the behalf of Associazione Italiana Radioterapia Oncologica (AIRO)

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Introduction: The integration between radiotherapy and drugs, from chemotherapy to recently available target therapies, continues to have a relevant role in the treatment of locally advanced and metastatic Non-small cell lung cancer (NSCLC). Aim of the present review is to evaluate the promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy. Areas covered: We searched Medline, Google Scholar, PubMed, ProQuest Dissertation, and Theses databases for reports published in English. A study was included when it reported on cancer-related radiotherapy and included patients with NSCLC treated with chemo and/or target therapies. Review articles were excluded from the analysis. Expert commentary: Chemo-radiotherapy still represents the standard of choice in locally advanced NSCLC, while to date the addition of target therapies to chemo-radiotherapy did not demonstrate any robust advantage in this stage of disease. Considering the absence of randomized controlled trials, the role of target therapies in early stage adjuvant NSCLC is not yet recommended in clinical practice. On the contrary, in the setting of oligometastatic and oligoprogressive disease, new molecules demonstrated to be safe and effective, opening to a promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy.

AB - Introduction: The integration between radiotherapy and drugs, from chemotherapy to recently available target therapies, continues to have a relevant role in the treatment of locally advanced and metastatic Non-small cell lung cancer (NSCLC). Aim of the present review is to evaluate the promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy. Areas covered: We searched Medline, Google Scholar, PubMed, ProQuest Dissertation, and Theses databases for reports published in English. A study was included when it reported on cancer-related radiotherapy and included patients with NSCLC treated with chemo and/or target therapies. Review articles were excluded from the analysis. Expert commentary: Chemo-radiotherapy still represents the standard of choice in locally advanced NSCLC, while to date the addition of target therapies to chemo-radiotherapy did not demonstrate any robust advantage in this stage of disease. Considering the absence of randomized controlled trials, the role of target therapies in early stage adjuvant NSCLC is not yet recommended in clinical practice. On the contrary, in the setting of oligometastatic and oligoprogressive disease, new molecules demonstrated to be safe and effective, opening to a promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy.

KW - early stage

KW - locally advanced

KW - Lung cancer

KW - oligometastatic

KW - radiotherapy

KW - target therapies

UR - http://www.scopus.com/inward/record.url?scp=85010908821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010908821&partnerID=8YFLogxK

U2 - 10.1080/14737140.2017.1273111

DO - 10.1080/14737140.2017.1273111

M3 - Review article

C2 - 27984919

AN - SCOPUS:85010908821

VL - 17

SP - 157

EP - 165

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 2

ER -